Share this post on:

AdipoRon

AdipoRon is an agonist at adiponectin receptors that increases secretion of AMPK and PPAR-α. AdipoRon exhibits anti-diabetic and cardioprotective activities and is in development as a potential treatment for type 2 diabetes mellitus (T2DM). In vivo, AdipoRon decreases insulin resistance and glucose tolerance, ameliorates diabetes, and increases lifespan. In animal models of myocardial ischemia/reperfusion, this compound improves cardiac function, decreases oxidative stress, and inhibits post-ischemic cardiomyocyte apoptosis.

References PubMed ID::http://www.ncbi.nlm.nih.gov/pubmed/18836071

Cas No.

924416-43-3

Purity

≥98%

Formula

C27H28N2O3

Formula Wt.

428.53

Chemical Name

2-(4-Benzoylphenoxy)-N-[1-(phenylmethyl)-4-piperidinyl]acetamide

IUPAC Name

2-(4-Benzoylphenoxy)-N-(1-benzyl-4-piperidinyl)acetamide

Solubility

Soluble in DMSO, 100% ethanol or methanol. Insoluble in water

Appearance

White solid

Zhang Y, Zhao J, Li R, et al. AdipoRon, the first orally active adiponectin receptor activator, attenuates postischemic myocardial apoptosis through both AMPK-mediated and AMPK-independent signalings. Am J Physiol Endocrinol Metab. 2015 Aug 1;309(3):E275-82.PMID: 26037251.

Okada-Iwabu M, Yamauchi T, Iwabu M, et al. A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Nature. 2013 Nov 28;503(7477):493-9. PMID: 24172895.

AZD-8055